ERIC 2018 | A perspective on the current landscape of CLL treatment

Eva Kimby

Eva Kimby, MD, PhD, of the Karolinska University Hospital, Solna, Sweden, discusses her thoughts on the current landscape of CLL treatment. Prof. Kimby covers the different therapeutic options available, including FCR chemotherapy, bendamustine, monoclonal antibodies and ibrutinib, considering the patient’s biomarker status, age and fitness. She also discusses considerations surrounding the use of ibrutinib in younger patients, expressing that long-term follow ups are still awaited. This video was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

Share this video